Medipure is a pharmaceutical incubator focussed on treating critical diseases on a global scale, striving to provide a new class of medications, improving patient safety, efficacy and quality of life ...
Our researchers are at the heart of Medipure’s science. Each is empowered with unique narratives of what motivates them to discover novel therapies. The passion and dedication that our team brings to work each day is a testament to the knowledge of the impact we can make in patients’ lives. As a biotech incubator, we believe in a “bench-to-bedside” drug approach in developing proprietary, novel drug molecules with safe and effective clinical and health outcomes.
Our drug discovery and development process starts and ends with the patient. Our research program is prioritized by understanding and validating the cause of the disease at the molecular level and then developing safe, optimized and effective medications based on our novel molecules. Research focuses on molecules that specifically target and regulate the endocannabinoid mechanism to achieve beneficial medicinal effects.
Our extensive experience in the discovery and development of prescription medicines as pharmaceutical products makes us one of the leading endocannabinoid therapeutic developers globally. We maintain in-house control over all aspects of the formulation and product development process – molecule discovery research, formulation and drug delivery technologies, clinical trials, and regulatory affairs. All of our research technologies are protected through our established IP partner.
As a pioneer in the novel molecule-based endocannabinoid-therapeutics, we are moving forward with our drug candidates in various preclinical and clinical stages targeting pain, anxiety, dermatitis & psoriasis management. The drug development portfolio is further extended to fatty liver diseases including NASH, arthritis and oncology. We seek to maximize the value of our products through rapid, cost-effective product development, addressing market needs, and establishing strategic partnerships.